MedTrace Logo

Omega 3 Fatty Acids in Patients With Chronic Renal Disease

NCT03280615 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-09-09

Study results available
· View outcomes & findings →

Summary

To study the tolerance and efficacy of an omega 3 fatty acids supplement on renal and vascular function and inflammatory parameters in patients with chronic renal disease

Conditions

  • Renal Insufficiency, Chronic

Interventions

DIETARY_SUPPLEMENT

Omega 3 fatty acids

Omega 3 fatty acids will be provided in a dose of 3.7 g/day, that should be enough to rise red blood cell levels of eicosapentanoic and docosahexanoic acids

DIETARY_SUPPLEMENT

Corn oil

Corn oil will be the placebo comparator for omega 3 fatty acids supplement

Sponsors & Collaborators

  • Servicio de Salud Metropolitano Oriente

    collaborator UNKNOWN

  • University of Chile

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-20
Primary Completion
2018-10-31
Completion
2018-10-31

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03280615 on ClinicalTrials.gov